{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:26Z","timestamp":1787169566807,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Levonadifloxacin is a novel broad-spectrum antibiotic belonging to the benzoquinolizine subclass of quinolones. It is available in intravenous as well as oral formulation for the treatment of infections caused by common Gram-positive bacterial pathogens including methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MRSA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This study retrospectively assessed the real-world safety and efficacy of levonadifloxacin (oral and\/or IV) in the treatment of 1229 patients across various clinical conditions. Study outcomes were clinical and microbiological success at the end of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean duration of levonadifloxacin therapy was 7.2 days, with a time to clinical improvement averaging at 4 days. Three hundred and three patients received oral therapy, 875 received IV, and 51 received a combination of IV followed by oral therapy. Patients were prescribed levonadifloxacin for skin and soft-tissue infections, diabetic foot infections, septicemia, catheter-related bloodstream infections, bone and joint infections, febrile neutropenia, and respiratory infections including COVID-19 pneumonia. High clinical success rates of 98.3%, 93.7%, and 96.1% with oral, IV, and IV followed by oral levonadifloxacin, respectively, were obtained. Only 11 mild adverse events were reported in 9 patients which included constipation, diarrhea, hyperglycemia, nausea, fatigue, and vomiting. Overall, 96.3% and 97.3% of investigators rated the efficacy and safety of levonadifloxacin as \u201cgood to excellent.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      An excellent safety and efficacy profile of levonadifloxacin was observed in this study making it a suitable treatment option for management of various bacterial infections, including those caused by resistant Gram-positive pathogens such as MRSA and quinolone-resistant\n                      <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijabmr.ijabmr_602_21","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T04:36:34Z","timestamp":1643603794000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prescription-Event Monitoring Study on Safety and Efficacy of Levonadifloxacin (Oral and I.V.) in Management of Bacterial Infections"],"prefix":"10.4103","volume":"12","author":[{"given":"Yatin","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand R.","family":"Sutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Zirpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Narendra","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakravarthi","family":"Alapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant C.","family":"Nagvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil Dev","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khokan","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"R2-7-20240902","doi-asserted-by":"crossref","first-page":"e1001974","DOI":"10.1371\/journal.pmed.1001974","article-title":"Antibiotic resistance in India: Drivers and opportunities for action","volume":"13","author":"Laxminarayan","year":"2016","journal-title":"PLoS Med"},{"key":"R3-7-20240902","doi-asserted-by":"crossref","first-page":"e00420","DOI":"10.1002\/prp2.420","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"6","author":"Monteiro","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"R4-7-20240902","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/1440-1681.13066","article-title":"Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice","volume":"46","author":"Zamoner","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R5-7-20240902","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-7-20240902","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"R7-7-20240902","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14787210.2019.1552518","article-title":"Management of bacterial skin and skin structure infections with polymicrobial etiology","volume":"17","author":"Esposito","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R8-7-20240902","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: Review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R10-7-20240902","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A comparative assessment of clinical pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin","volume":"37","author":"Bakthavatchalam","year":"2019","journal-title":"Indian J Med Microbiol"},{"key":"R11-7-20240902","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"Bhagwat","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-7-20240902","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1099\/jmm.0.001102","article-title":"Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations","volume":"68","author":"Dubois","year":"2019","journal-title":"J Med Microbiol"},{"key":"R13-7-20240902","first-page":"2156","article-title":"Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"Bakthavatchalam","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R14-7-20240902","first-page":"30","article-title":"Efficacy and safety of a novel broad-spectrum Anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: A phase 3, openlabel, randomized study","volume":"68","author":"Bhatia","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"R15-7-20240902","doi-asserted-by":"crossref","first-page":"e01067","DOI":"10.1016\/j.heliyon.2018.e01067","article-title":"Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention","volume":"4","author":"Khatoon","year":"2018","journal-title":"Heliyon"},{"key":"R16-7-20240902","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin-and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis","year":"2019","journal-title":"J Med Microbiol"},{"key":"R17-7-20240902","first-page":"e02297","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-7-20240902","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1080\/22221751.2020.1812437","article-title":"Risks and features of secondary infections in severe and critical ill COVID-19 patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg Microbes Infect"}],"container-title":["International Journal of Applied &amp; Basic Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijabmr.ijabmr_602_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:50Z","timestamp":1787166530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijabmr.ijabmr_602_21"}},"subtitle":["Findings of Real-World Observational Study"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijabmr.ijabmr_602_21","relation":{},"ISSN":["2229-516X"],"issn-type":[{"value":"2229-516X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}